J. Shefner, Jinsy A. Andrews, L. Meng
Dec 18, 2014
Citations
0
Influential Citations
3
Citations
Journal
F1000Research
Abstract
TIRASEMTIV MAXIMUM TOLERATED DOSE AND SVC AT WEEK 12 TIRASEMTIV LEVELS AND MUSCLE STRENGTH MEASURED BY HAND-HELD DYNAMOMETRY (HHD) – Earlier, small Phase 2a studies of tirasemtiv, a fast skeletal muscle troponin activator, suggested trends to improved function in patients with ALS – BENEFIT-ALS was a Phase 2b study that evaluated the effects of tirasemtiv in 711 patients with ALS – After 12 weeks of double-blind treatment, statistically significant differences favoring tirasemtiv were found in extremity strength and in slow vital capacity (SVC), although there was no significant difference between groups in ALSFRS-R